Co-Authors
This is a "connection" page, showing publications co-authored by FREDRICK B HAGEMEISTER and MARIA A RODRIGUEZ.
Connection Strength
2.542
-
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8.
Score: 0.123
-
Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):384-91.
Score: 0.119
-
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(?) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013 Sep; 162(5):631-8.
Score: 0.113
-
Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8.
Score: 0.112
-
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):15-8.
Score: 0.108
-
NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec; 17(6 Suppl 10):34-8; discussion 38-40.
Score: 0.094
-
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 01; 23(4):667-75.
Score: 0.062
-
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep. 2003 Sep-Oct; 10(5):1513-8.
Score: 0.057
-
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol. 2000; 11 Suppl 1:137-40.
Score: 0.044
-
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24.
Score: 0.044
-
ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999 Jun 01; 93(11):3632-6.
Score: 0.043
-
Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999 May 01; 93(9):3081-7.
Score: 0.042
-
The clinical significance of molecular response in indolent follicular lymphomas. Blood. 1998 Apr 15; 91(8):2955-60.
Score: 0.039
-
Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. Leuk Lymphoma. 1998 Jan; 28(3-4):295-306.
Score: 0.039
-
Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol. 1997 Dec; 15(12):3488-95.
Score: 0.038
-
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995 Jul; 13(7):1734-41.
Score: 0.032
-
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul; 6(6):609-11.
Score: 0.032
-
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
Score: 0.032
-
Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82.
Score: 0.032
-
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun; 169(6):814-23.
Score: 0.032
-
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84.
Score: 0.030
-
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
Score: 0.030
-
Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol. 1994 Apr; 31(2 Suppl 3):36-43.
Score: 0.030
-
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6.
Score: 0.029
-
Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol. 1994; 5 Suppl 2:41-6.
Score: 0.029
-
The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol. 1994; 5 Suppl 2:59-63.
Score: 0.029
-
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
Score: 0.029
-
Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol. 1993 Feb; 4(2):125-31.
Score: 0.027
-
A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol. 1992 Nov; 3(9):711-7.
Score: 0.027
-
NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann Oncol. 1992 Sep; 3 Suppl 4:87-90.
Score: 0.027
-
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8.
Score: 0.026
-
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma. 2012 May; 53(5):801-6.
Score: 0.025
-
Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2012 Jan; 53(1):50-6.
Score: 0.025
-
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.
Score: 0.025
-
Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood. 1991 Mar 01; 77(5):942-7.
Score: 0.024
-
Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. Ann Oncol. 1991 Jan; 2(1):25-31.
Score: 0.024
-
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):200-8.
Score: 0.023
-
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 01; 27(31):5213-8.
Score: 0.022
-
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15; 113(10):2734-41.
Score: 0.020
-
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008 Nov; 143(3):355-60.
Score: 0.020
-
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol. 1988 Apr; 25(2 Suppl 2):47-50.
Score: 0.020
-
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol. 2008 Mar; 19(3):553-9.
Score: 0.019
-
Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol. 2007 Aug; 82(8):725-8.
Score: 0.019
-
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5.
Score: 0.019
-
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Feb; 136(3):439-47.
Score: 0.018
-
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006 Nov 15; 194(10):1394-7.
Score: 0.018
-
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Sep; 47(9):1818-21.
Score: 0.018
-
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006 Apr 01; 24(10):1582-9.
Score: 0.017
-
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Mar; 47(3):481-5.
Score: 0.017
-
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23.
Score: 0.016
-
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer. 2005 Jul 15; 104(2):345-53.
Score: 0.016
-
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102.
Score: 0.015
-
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res. 2004 Aug 15; 10(16):5432-8.
Score: 0.015
-
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
Score: 0.015
-
Thalidomide for patients with recurrent lymphoma. Cancer. 2004 Mar 15; 100(6):1186-9.
Score: 0.015
-
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol. 2004 Feb; 27(1):73-80.
Score: 0.015
-
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003 Jul 15; 98(2):310-4.
Score: 0.014
-
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003 Jun 01; 21(11):2115-22.
Score: 0.014
-
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003 Feb 01; 97(3):586-91.
Score: 0.014
-
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Jan 01; 55(1):36-43.
Score: 0.014
-
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 2002 Dec 15; 100(13):4351-7.
Score: 0.013
-
Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park). 2002 Aug; 16(8 Suppl 7):27-31.
Score: 0.013
-
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2001 Jul; 12(7):923-7.
Score: 0.012
-
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma. 2001 Jun; 2(1):40-6.
Score: 0.012
-
Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma. 2001 May; 41(5-6):535-44.
Score: 0.012
-
Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol. 2001 Jan 15; 19(2):398-405.
Score: 0.012
-
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000 Dec; 27(6 Suppl 12):37-41.
Score: 0.012
-
Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol. 2000 Dec; 11(12):1551-6.
Score: 0.012
-
Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma. 2000 Oct; 39(3-4):291-9.
Score: 0.012
-
Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000 Sep; 39(1-2):77-85.
Score: 0.012
-
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20.
Score: 0.012
-
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000 Jan; 11(1):69-72.
Score: 0.011
-
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95.
Score: 0.011
-
Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999 Apr; 10(4):433-40.
Score: 0.011
-
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood. 1999 Apr 01; 93(7):2202-7.
Score: 0.011
-
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest New Drugs. 1999; 17(2):187-92.
Score: 0.010
-
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9.
Score: 0.010
-
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol. 1998 Dec; 103(3):678-83.
Score: 0.010
-
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Dec; 32(1-2):97-106.
Score: 0.010
-
Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997. Radiology. 1998 Sep; 208(3):739-47.
Score: 0.010
-
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol. 1998 May; 9(5):511-8.
Score: 0.010
-
Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998 Feb 15; 91(4):1178-84.
Score: 0.010
-
Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):377-86.
Score: 0.010
-
Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys. 1997 Oct 01; 39(3):609-16.
Score: 0.009
-
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1997 Jun; 26(1-2):77-82.
Score: 0.009
-
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol. 1997 Feb; 96(2):328-32.
Score: 0.009
-
Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol. 1997; 8 Suppl 1:129-31.
Score: 0.009
-
No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol. 1996 Feb; 14(2):543-8.
Score: 0.008
-
High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol. 1996 Feb; 7(2):157-63.
Score: 0.008
-
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1996 Jan; 14(1):233-9.
Score: 0.008
-
Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma. 1995 Jun; 18(1-2):87-92.
Score: 0.008
-
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1995 Mar; 13(3):583-7.
Score: 0.008
-
Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study. Clin Oncol (R Coll Radiol). 1995; 7(5):300-3.
Score: 0.008
-
Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):3-11.
Score: 0.008
-
Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol. 1994 Nov; 5(9):847-9.
Score: 0.008
-
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun; 12(6):1169-76.
Score: 0.008
-
Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer. 1994 May 01; 73(9):2408-16.
Score: 0.007
-
Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994 Mar; 12(3):575-9.
Score: 0.007
-
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest New Drugs. 1994; 12(3):217-22.
Score: 0.007
-
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol. 1994; 5 Suppl 2:73-7.
Score: 0.007
-
Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. Ann Oncol. 1994; 5 Suppl 2:97-100.
Score: 0.007
-
CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol. 1993 Mar; 4(3):205-11.
Score: 0.007
-
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992 May; 10(5):790-4.
Score: 0.007
-
Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1992; 23(2):407-12.
Score: 0.006
-
Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med. 1991 May 15; 114(10):855-60.
Score: 0.006
-
Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol. 1991 Feb; 9(2):236-42.
Score: 0.006
-
Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol. 1990 Apr; 8(4):615-22.
Score: 0.006
-
A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989 Oct; 7(10):1518-27.
Score: 0.005
-
Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med. 1989 Aug; 87(2):167-72.
Score: 0.005
-
Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst. 1988 Nov 02; 80(17):1408-12.
Score: 0.005